<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helfand, S C</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Low-dose cytosine arabinoside-induced remission of lymphoblastic leukemia in a cat.</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Veterinary Medical Association</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J. Am. Vet. Med. Assoc.</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Cat Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Cats</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytarabine</style></keyword><keyword><style  face="normal" font="default" size="100%">Leukemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Leukemia Virus, Feline</style></keyword><keyword><style  face="normal" font="default" size="100%">Leukemia, Lymphoid</style></keyword><keyword><style  face="normal" font="default" size="100%">Remission Induction</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1987</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1987 Sep 15</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">191</style></volume><pages><style face="normal" font="default" size="100%">707-10</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Low-dose cytosine arabinoside (10 mg/m2, q 12 h), an antimetabolite chemotherapeutic agent, was administered subcutaneously to a cat with aleukemic lymphoblastic leukemia. After several weeks of this treatment, there was marked improvement in the neutrophil count and PCV, as well as restoration of adequate numbers of normal bone marrow cells. The remission lasted 10 weeks.</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/2824412?dopt=Abstract</style></custom1></record></records></xml>